Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00189904 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Phase 1 study of HIV Infections, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 5
- Study locations
NCT00189904: Completed Phase 1 study of HIV Infections, sponsored by Bavarian Nordic.
NCT00189904 is a Phase 1 study of HIV Infections that has completed, run by Bavarian Nordic. The registered enrollment target is 151 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00189904, a Phase 1 study of HIV Infections, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.
Conditions Studied
Interventions
- BIOLOGICAL IMVAMUNE (MVA-BN)
Study Locations (5)
Indiana
- Indiana University School of Medicine - Indianapolis
Kentucky
- University of Kentucky Medical Center - Lexington
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt AIDS Clinical Trials Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00189904
The ClinicalTrials.gov registry entry for NCT00189904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which IMVAMUNE (MVA-BN) is the first listed.
NCT00189904 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Indiana, Kentucky, Missouri.
Frequently Asked Questions
What is clinical trial NCT00189904 about?
NCT00189904 is a clinical study titled "Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients". The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.
What is the current status of trial NCT00189904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2005-07.
What conditions does trial NCT00189904 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00189904?
The interventions under investigation include: IMVAMUNE (MVA-BN) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00189904?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00189904 being conducted?
This trial has 5 study locations across Indiana, Kentucky, Missouri, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.